Lingrui Group, a shareholder of Lingrui Pharmaceutical, has released 9.75 million pledged shares, representing 8% of its holdings and 1.72% of the company's total share capital, and subsequently re-pledged 5.08 million shares, accounting for 4.17% of its holdings and 0.9% of the total share capital. As of the announcement date, Lingrui Group has a cumulative pledge of 32.93 million shares, representing 27.03% of its holdings and 5.81% of the company's total share capital. In the first quarter of 2026, Lingrui Pharmaceutical achieved revenue of 1.126 billion yuan and net profit attributable to the parent company of 246 million yuan.
Henan Lingrui Pharmaceutical Co LtdShareholder pledge changes may signal financial strain but no direct impact on company operations.
Lingrui Group unpledged and re-pledged shares, indicating potential liquidity needs or financial pressure.